Alternatives to Advanced Accelerator Applications

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

A commercial-stage immunotherapy company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases.

Developing microbiome-derived therapies to overcome resistance to immune checkpoint inhibitors in cancer treatment.

A University of Cambridge spin-out tackling unmet drug screening needs by combining materials engineering and cell biology.

A leading global contract development and manufacturing organization (CDMO) for innovative biologic and small molecule therapies.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Azurity Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing high-quality, affordable liquid medications.

Biotechnology company developing and commercializing cell therapies for cancer treatment.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.

Robotic avatars and AI agents for pharmaceutical and medical cleanrooms to eliminate human contamination.

Developing TCR-mimetic antibody therapies to treat cancer by targeting peptide-loaded major histocompatibility complexes.